E
TGTX icon

Ergoteles’s TG Therapeutics TGTX Stock Holding History

Ergoteles’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-55,632
Closed -$1.38M – 765
2023
Q2 		$1.38M Buy
+55,632
New +$1.44M 0.07% 365
2023
Q1 		– Sell
-126,383
Closed -$1.5M – 1747
2022
Q4 		$1.5M Buy
+126,383
New +$917K 0.05% 349
2022
Q2 		– Sell
-34,750
Closed -$330K – 1997
2022
Q1 		$330K Buy
+34,750
New +$402K 0.01% 810
2021
Q4 		– Sell
-87,711
Closed -$2.92M – 1588
2021
Q3 		$2.92M Buy
+87,711
New +$2.71M 0.11% 208
2021
Q2 		– Sell
-40,100
Closed -$1.93M – 1688
2021
Q1 		$1.93M Buy
+40,100
New +$1.93M 0.06% 286

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Ergoteles's TGTX Position: Q3 2023 in Review

Ergoteles sold out of TG Therapeutics (TGTX) in Q3 2023, closing a stake of 55,632 shares — an estimated $1.38M sold.

Ergoteles first reported a position in TGTX in Q1 2021 and held it in 5 quarters. The position peaked at $2.92M in Q3 2021. 236 funds tracked by Wall St. Rank hold TGTX as of Q3 2023.

  • Ergoteles reported no remaining TG Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 55,632 TG Therapeutics shares in Q3 2023, an estimated $1.38M.
  • Ergoteles first reported a position in TG Therapeutics in Q1 2021 and held it in 5 quarters.
  • Ergoteles's TG Therapeutics position peaked at $2.92M in Q3 2021.
  • 236 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.